Epitalon

Overview

Epitalon (also written Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), designed as a simplified analog of epithalamin, a peptide extract of the pineal gland. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, where much of the foundational research on the broader class of "short peptide bioregulators" originates. In published research, Epitalon has been examined primarily as a geroprotective and circadian-regulating compound. Laboratory studies report that it can upregulate telomerase and elongate telomeres in cultured human cells, while animal studies have looked at its effects on melatonin rhythms, biomarkers of aging, and lifespan in rodents and other models. The bulk of the evidence is preclinical (cell culture and animal); human data are limited to small studies, several conducted in Russia. Epitalon has not been evaluated in large, controlled clinical trials measuring longevity or telomere outcomes in people, and much of the surrounding popular narrative outpaces the peer-reviewed record. This profile summarizes what the published literature has examined, not any recommendation for use. Epitalon is one of seven compounds on the FDA Pharmacy Compounding Advisory Committee's July 23–24, 2026 docket, where the non-binding vote concerns whether to recommend moving it toward the 503A Bulks List — an early step in a longer regulatory process.

Mechanism of action

The most-studied proposed mechanism is transcriptional: in cell-culture research, Epitalon is reported to induce expression of the telomerase catalytic subunit (hTERT), increase telomerase enzymatic activity, and thereby elongate telomeres in somatic cells that are normally telomerase-negative. A 2025 independent study at Brunel University London (Al-Dulaimi et al., Biogerontology) reported hTERT upregulation and telomerase-mediated telomere elongation in normal human cell lines (IBR.3 fibroblasts and HMEC epithelial cells), while in two breast cancer lines (21NT, BT474) hTERT mRNA rose but telomerase activity did not, and telomere extension instead tracked with activation of the alternative lengthening of telomeres (ALT) pathway; the authors reported that ALT induction was largely specific to the cancer lines rather than the normal cells. A second line of research centers on the pineal gland: Epitalon and its parent extract epithalamin are reported to restore or enhance nocturnal melatonin synthesis and to modulate circadian clock genes in preclinical models. Additional preclinical work describes antioxidant and antimutagenic effects, including reduced chromosome aberrations in animal tissue. As a very short peptide, Epitalon is proposed to act as a gene-regulatory bioregulator rather than a classical receptor agonist, though the precise molecular pathways linking the peptide to hTERT transcription remain incompletely characterized.

What published research has examined

Published research has examined Epitalon mainly in the contexts of cellular aging and telomere biology, circadian and neuroendocrine regulation, and geroprotection. In vitro studies have investigated telomerase induction and telomere elongation in human fibroblasts and other cell lines, including extension of replicative lifespan beyond the Hayflick limit without reported malignant transformation. Animal studies (primarily mice and rats, with some earlier work in other models) have explored effects on lifespan and age-related markers, reproductive and hormonal changes, spontaneous tumor incidence, and melatonin secretion in aged animals. A small number of human studies, largely from the St. Petersburg group, have looked at circadian melatonin output and at ophthalmologic outcomes such as retinitis pigmentosa. Across these areas the evidence remains predominantly preclinical, and human findings come from small studies rather than large randomized controlled trials. Nothing here should be read as establishing efficacy for any human condition.

Safety considerations in the literature

Reported safety information comes largely from animal studies and small human studies conducted by the originating Russian research group, where Epitalon was generally described as well tolerated in the tested settings and, in rodent work, not associated with increased spontaneous tumor incidence. However, the published safety record is thin by modern regulatory standards: there are no large, long-term controlled human trials, limited data on the purity and immunogenicity of injectable preparations, and little characterization of the long-term effects of chronic telomerase activation in humans. Because a central proposed mechanism is upregulation of telomerase and telomere lengthening — pathways also relevant to cancer cell biology, and the 2025 Brunel study reported ALT-pathway activation in the tested cancer lines — the theoretical oncologic implications remain an open research question rather than a settled conclusion. Reviewers have noted that Epitalon lacks sufficient physico-chemical characterization and human safety and effectiveness data, and have called for further short- and long-term toxicity studies before any regulatory approval. This is a research summary and not a statement about safety for human use.

Key published studies

Regulatory status

Current status: Category 2 · PCAC July 2026 docket. Not FDA approved. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.

Related compounds

Read our full guide on whether peptides are safe.